Galinelli Nicolas C, Bamford Nicholas J, Erdody Madison L, Mackenzie Skye A, Warnken Tobias, Harris Patricia A, Sillence Martin N, Bailey Simon R
Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.
Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
Equine Vet J. 2025 Feb 18. doi: 10.1111/evj.14468.
Due to the high frequency of laminitis reported for both conditions, the relationship between pituitary pars intermedia dysfunction (PPID) and insulin dysregulation (ID), and the potential role of dopamine in modifying insulin secretion, requires further investigation.
To evaluate the effect of pergolide mesylate on insulin sensitivity and postprandial insulin and glucose responses in horses and ponies with ID, both with or without concurrent PPID.
Randomised crossover study.
Sixteen horses and ponies, comprising eight matched pairs (PPID+ID or ID-only), were given pergolide mesylate at a dose of 2 μg/kg bwt orally once daily for 4 weeks (plus a 4-week non-treatment control period, with a 4-week washout between phases). A combined glucose and insulin tolerance test (CGIT) and a standard meal test (SMT; containing 1.1 g/kg bwt of starch and 0.1 g/kg bwt of free sugars), were performed before and after each treatment period to determine insulin sensitivity and postprandial insulin and glucose responses, respectively. Variables derived from the CGIT and SMT were analysed using linear mixed models.
Pergolide treatment did not alter any of the variables derived from the CGIT in either the PPID+ID or ID-only groups (all p > 0.05). For the SMT, insulin responses were reduced by pergolide treatment for the PPID+ID group, with Δ change values for the total area under the curve for insulin over 300 mins (estimated marginal mean [95% confidence interval]) being -25.4 (-39.9 to -7.3) min∙mIU/mL (p = 0.03) and Δ change values for peak insulin concentration being -100 (-167 to -29) μIU/mL (p = 0.04). No effect of pergolide treatment was detected for the ID-only group.
Number of animals and heterogeneity among groups.
Pergolide had no effect on tissue insulin sensitivity. However, the results suggest that postprandial hyperinsulinaemia may be limited by this dopamine receptor agonist in animals with PPID plus ID.
由于两种病症中均有较高频率的蹄叶炎报道，垂体中间叶功能障碍（PPID）与胰岛素调节异常（ID）之间的关系，以及多巴胺在调节胰岛素分泌中的潜在作用，需要进一步研究。
评估甲磺酸培高利特对患有ID的马和矮种马（无论是否并发PPID）的胰岛素敏感性以及餐后胰岛素和葡萄糖反应的影响。
随机交叉研究。
16匹马和矮种马，包括8对匹配组（PPID + ID或仅ID），每天口服一次甲磺酸培高利特，剂量为2μg/kg体重，持续4周（外加4周的非治疗对照期，各阶段之间有4周的洗脱期）。在每个治疗期前后分别进行葡萄糖和胰岛素联合耐量试验（CGIT）和标准餐试验（SMT；含1.1g/kg体重的淀粉和0.1g/kg体重的游离糖），以分别确定胰岛素敏感性以及餐后胰岛素和葡萄糖反应。使用线性混合模型分析从CGIT和SMT得出的变量。
在PPID + ID组或仅ID组中，培高利特治疗均未改变从CGIT得出的任何变量（所有p>0.05）。对于SMT，培高利特治疗使PPID + ID组的胰岛素反应降低，胰岛素在300分钟内曲线下总面积的变化值（估计边际均值[95%置信区间]）为-25.4（-39.9至-7.3）min∙mIU/mL（p = 0.03），峰值胰岛素浓度的变化值为-100（-167至-29）μIU/mL（p = 0.04）。未检测到培高利特治疗对仅ID组有影响。
动物数量和组间异质性。
培高利特对组织胰岛素敏感性无影响。然而，结果表明，在患有PPID加ID的动物中，这种多巴胺受体激动剂可能会限制餐后高胰岛素血症。
